Centurion Ilac Sanayi VE Ticaret AN

Centurion Ilac Sanayi ve Ticaret Anonim Şirketi, commonly known as Centurion Pharma, is a privately-owned Turkish pharmaceutical company specializing in the research, development, manufacturing, and marketing of a diverse range of pharmaceutical products. Established in 1949 and incorporating Centurion, an American company, in 1999, Centurion Pharma has grown to become a significant player in the Turkish pharmaceutical industry. (centurion.com.tr)

The company operates its own manufacturing facility in Ankara, Turkey, adhering to international quality standards such as Good Manufacturing Practices (GMP). Centurion Pharma focuses on delivering high-quality, effective, and accessible medicines across various therapeutic categories, including vaccines, biosimilars, and orphan drugs. (centurion.com.tr)

Centurion Pharma's distribution network is robust, encompassing both domestic and international markets. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's extensive import and export activities suggest a well-established infrastructure. Centurion Pharma imports pharmaceutical products from various countries, including India, China, Germany, the Netherlands, and Italy, indicating a broad geographic coverage.

Centurion Pharma plays a multifaceted role in Turkey's pharmaceutical supply chain. As a manufacturer, it produces a wide array of pharmaceutical products, including vaccines, biosimilars, and orphan drugs. Additionally, the company imports pharmaceutical products from various countries, including India, China, Germany, the Netherlands, and Italy, indicating a broad geographic coverage. This dual role positions Centurion Pharma as both a producer and importer, contributing significantly to the availability and diversity of pharmaceutical products in the Turkish market.

Centurion Pharma's sourcing strategy reveals a notable concentration in its supplier base. The company's import data indicates a significant reliance on a single supplier, Indian Immunologicals Limited, which accounts for 50 shipments valued at $2.4 million USD. This single-source dependency could pose risks related to supply chain disruptions, pricing volatility, and potential challenges in negotiating favorable terms.

The shipment data suggests a stable relationship with Indian Immunologicals Limited, as evidenced by the consistent volume and value of imports over time. However, the lack of diversification in suppliers may limit Centurion Pharma's ability to mitigate risks associated with supply chain disruptions or changes in supplier performance.

Centurion Pharma's supply chain resilience appears to be heavily dependent on its relationship with Indian Immunologicals Limited. The absence of backup suppliers for its imported products indicates a potential vulnerability to disruptions in the supply chain. Additionally, the limited diversity in imported formulations, with only 19 unique formulations, suggests a narrow product range that may not fully meet the diverse needs of the Turkish market.

The company's reliance on a single supplier and limited product diversity may expose it to risks related to supply chain disruptions, regulatory changes, or shifts in market demand. To enhance resilience, Centurion Pharma may consider diversifying its supplier base and expanding its product portfolio to better serve the evolving needs of the Turkish pharmaceutical market.

Centurion Pharma's concentrated sourcing pattern positions it as a significant partner for Indian pharmaceutical exporters, particularly those specializing in vaccines and medical devices. The company's focus on these product categories aligns with India's strengths in vaccine production and medical device manufacturing. For Indian exporters, establishing or strengthening partnerships with Centurion Pharma could lead to increased market penetration in Turkey, leveraging Centurion Pharma's established distribution network and market knowledge.

However, the limited supplier diversification within Centurion Pharma's sourcing strategy may present challenges in negotiating favorable terms and mitigating risks associated with supply chain disruptions. Indian exporters seeking to become alternative suppliers should consider offering competitive pricing, reliable delivery schedules, and high-quality products to meet Centurion Pharma's standards and requirements.

In Turkey, the Ministry of Health (MoH) serves as the primary regulatory authority overseeing pharmaceutical imports. The MoH enforces regulations that govern the importation, marketing, and distribution of pharmaceutical products to ensure public health and safety. Key legislation includes the Pharmaceutical and Medicinal Products Regulation, which outlines the requirements for importing pharmaceutical products, including the need for an import license and a certificate of control from the MoH.

The marketing authorization pathway for Indian generics involves obtaining approval from the MoH, which includes submitting a comprehensive dossier demonstrating the product's quality, safety, and efficacy. This process ensures that imported generics meet the standards set by Turkish authorities and are suitable for the Turkish market.

Import licensing requirements in Turkey stipulate that pharmaceutical products must be accompanied by a certificate of control issued by the MoH. This certificate is obtained prior to importation and requires documentation such as a pro forma invoice, certificate of analysis, and an approved health certificate from the country of origin. The certificate of control is valid for 12 months, ensuring that imported products meet Turkish standards.

Good Manufacturing Practice (GMP) certification is recognized by the MoH, and imported pharmaceutical products must comply with GMP standards. Indian exporters seeking to supply Centurion Pharma and the Turkish market must ensure that their manufacturing facilities are GMP-compliant to meet regulatory requirements.

Imported pharmaceutical products are subject to batch testing and stability requirements as mandated by the MoH. These tests ensure that products maintain their quality, safety, and efficacy throughout their shelf life. Labeling requirements include providing information in Turkish, ensuring that consumers and healthcare professionals can understand product details. Serialization mandates may also be in place to enhance traceability and prevent counterfeit products.

Between 2024 and 2026, Turkey has implemented policy changes affecting pharmaceutical imports, including updates to the Pharmaceutical and Medicinal Products Regulation. These changes may involve stricter quality control measures, revised import licensing procedures, and enhanced requirements for product documentation. Indian pharmaceutical exporters should stay informed about these regulatory updates to ensure compliance and maintain uninterrupted access to the Turkish market.

Centurion Pharma's product strategy focuses on therapeutic areas such as vaccines, biosimilars, and orphan drugs. The company's import data indicates a significant investment in vaccines and medical devices, with imports valued at $2.1 million and $1.7 million USD, respectively. This focus aligns with the growing demand for immunization and specialized treatments in Turkey.

The market demand for these products is driven by factors such as an aging population, increasing prevalence of chronic diseases, and a heightened awareness of preventive healthcare. Centurion Pharma's strategic emphasis on these areas positions it to address critical healthcare needs and expand its market presence.

Centurion Pharma's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from countries like India. The company's reliance on a single supplier, Indian Immunologicals Limited, suggests a focused approach to procurement. This strategy may be driven by considerations such as product quality, cost-effectiveness, and supplier reliability.

India's established reputation in vaccine production and pharmaceutical manufacturing aligns with Centurion Pharma's sourcing needs, enabling the company to offer a diverse range of products to the Turkish market.

Centurion Pharma serves multiple segments of the Turkish pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's importation of vaccines and medical devices indicates a strong presence in the hospital and healthcare sectors, where such products are essential. Additionally, Centurion Pharma's focus on orphan drugs and biosimilars positions it to cater to specialized treatment needs, further enhancing its market positioning.

There is a realistic opportunity for new Indian suppliers to partner with Centurion Pharma, particularly in the areas of vaccines and medical devices. The company's existing relationship with Indian Immunologicals Limited demonstrates a successful sourcing model that new suppliers can emulate. However, to establish a partnership, Indian exporters must meet Centurion Pharma's quality standards, comply with Turkish regulatory requirements, and offer competitive pricing.

Gaps in Centurion Pharma's current sourcing include a limited supplier base and a narrow product portfolio. New Indian suppliers can address these gaps by providing alternative products, diversifying the supplier base, and offering innovative solutions to meet the evolving needs of the Turkish pharmaceutical market.

Indian exporters seeking to supply Centurion Pharma and the Turkish market must ensure that their manufacturing facilities are GMP-compliant. Additionally, products must meet Turkish regulatory standards, including obtaining the necessary import licenses and certificates of control from the MoH. Labeling must be in Turkish, and products should comply with batch testing, stability requirements, and serialization mandates as specified by Turkish authorities.

To build a relationship with Cent